Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

2008297 citationsJournal Articlegreen Open Access

Authors

Matthew J. McGirt

Khoi D. Than · Johns Hopkins University

Jon Weingart · Johns Hopkins University

Kaisorn L. Chaichana · Johns Hopkins University

Frank J. Attenello · Johns Hopkins University

Alessandro Olivi · Johns Hopkins University

John Laterra · Johns Hopkins University

Abstract

In this experience, concomitant TMZ therapy in addition to Gliadel wafer implantation was associated with a median survival of nearly 21 months without increased perioperative morbidity. Temozolomide can be safely administered to patients receiving Gliadel wafers after resection of GBM.

Topics & Keywords

Glioma Diagnosis and Treatment Meningioma and schwannoma management Brain Metastases and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of neurosurgery

Volume 110, Issue 3, pp. 583-588

DOI: 10.3171/2008.5.17557

Field-Weighted Citation Impact: 8.36